We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Low Serum Creatinine Associated with Diabetes Risk

By LabMedica International staff writers
Posted on 02 May 2019
Creatinine is the only metabolite of creatine phosphate in the skeletal muscle and under the steady state; it is created at a relatively constant rate by the body depending on the total skeletal muscle mass.

Because of the close association between muscle mass and creatinine (correlation coefficient equal to or greater than 0.7), serum creatinine is also used as an inexpensive, easily available surrogate of muscle mass when the kidney functions are stable and protein intake is normal.

Scientists at the National Center for Global Health and Medicine (Tokyo, Japan) and their colleagues conducted a prospective analysis using data from 31,343 men aged between 20 to 64 years without diabetes at baseline from the Japan Epidemiology Collaboration on Occupational Health Study. More...
Participants were followed for a median of 7.7 years until March 2017 and separated into four groups based on baseline serum creatinine levels: less than 0.7 mg/dL (n = 1,492; mean age, 44.9 years), 0.7 mg/dL to 0.79 mg/dL (n = 6,405; mean age, 42.6 years), 0.8 mg/dL to 0.89 mg/dL (n = 10,848; mean age, 42.1 years) and 0.9 mg/dL to 1.2 mg/dL (n = 12,598; mean age, 43.6 years).

The team assessed the levels of serum creatinine using the enzymatic method and identified 2,509 cases of diabetes in the study cohort. The plasma glucose was measured using either the enzymatic or glucose oxidase peroxidative electrode method. HbA1c was measured using a latex agglutination immunoassay, high-performance liquid chromatography, or the enzymatic method. They defined diabetes as either HbA1c levels ≥6.5%, random glucose levels ≥200 mg/dL, fasting glucose levels ≥126 mg/dL or receiving antidiabetic treatment. The participants who met any of the aforementioned conditions during follow up were treated as incident cases of type 2 diabetes.

Men with serum creatinine levels of less than 0.7 mg/dL were at the highest risk for the condition (HR = 1.56)) compared with men with levels of 0.9 mg/dL to 1.2 mg/dL even after adjustments for age, smoking status, BMI, hypertension and dyslipidemia. Men with serum creatinine levels of 0.7 mg/dL to 0.79 mg/dL (HR = 1.22 and 0.8 mg/dL to 0.89 mg/dL (HR = 1.06) also were at higher fully adjusted risk compared with men with levels of 0.9 mg/dL to 1.2 mg/dL. The scientists further observed that men who were aged 45 years or older had higher risk in all creatinine groups compared with men who were younger than 45 years.

The team concluded that in their study based on repeated measurements of serum creatinine shows that low serum creatinine is associated with an increased risk of diabetes. Screening serum creatinine levels can be used to identify those at a high risk of diabetes. Huanhuan Hu, PhD, the lead author of study, said, “Skeletal muscle is a primary target for insulin action. Thus, decreased skeletal muscle mass could potentially trigger insulin resistance, which is an underlying mechanism of diabetes.” The study was published originally published on February 12, 2019, in the Journal of Diabetes Investigation.

Related Links:
National Center for Global Health and Medicine


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The assay evaluates tumor-derived total nucleic acid extracted from CSF and detects multiple biomarker classes (Photo courtesy of Shutterstock)

New CSF Liquid Biopsy Assay Reveals Genomic Insights for CNS Tumors

Central nervous system (CNS) malignancies pose distinctive diagnostic challenges because tissue-based testing is often infeasible and the blood–brain barrier limits the usefulness of plasma liquid biopsy.... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.